rs11061937 — ADIPOR2 ADIPOR2 rs11061937

Intronic ADIPOR2 variant associated with cardiovascular disease risk in individuals with impaired glucose tolerance, influencing adiponectin receptor 2 signaling and hepatic lipid and glucose metabolism

See your personal result for ADIPOR2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ADIPOR2 rs11061937: Hepatic Adiponectin Signaling and Cardiometabolic Risk

Adiponectin is one of the most abundant hormones secreted by fat tissue, and unlike most adipokines its levels paradoxically fall as body fat increases. Low circulating adiponectin is strongly associated with insulin resistance, type 2 diabetes, and cardiovascular disease11 Low circulating adiponectin is strongly associated with insulin resistance, type 2 diabetes, and cardiovascular disease
Adiponectin acts as a key anti-inflammatory, insulin-sensitizing signal; its decline in obesity is a central mechanism linking excess body fat to metabolic dysfunction. The metabolic effects of adiponectin are transmitted through two receptors: ADIPOR1, dominant in skeletal muscle, and ADIPOR2, dominant in the liver. rs11061937 is an intronic variant in the ADIPOR2 gene — it does not change the receptor's amino acid sequence but may influence receptor expression levels or splicing, thereby modulating how efficiently the liver responds to adiponectin's metabolic instructions.

The Mechanism

ADIPOR2 in the liver activates two interconnected metabolic pathways downstream of adiponectin binding: the AMPK pathway22 AMPK pathway
AMP-activated protein kinase — a master metabolic sensor that switches cells from anabolic to catabolic mode, increasing fatty acid oxidation and glucose uptake while suppressing fat synthesis and the PPARα pathway33 PPARα pathway
Peroxisome proliferator-activated receptor alpha — a nuclear receptor that governs transcription of genes for hepatic fatty acid oxidation and lipid export; ADIPOR2 is the primary activator of PPARα in liver. Together these pathways reduce hepatic fat accumulation, improve insulin sensitivity, and regulate LDL clearance and cholesterol synthesis. When ADIPOR2 expression is reduced — as occurs in obesity — PPARα activity in the liver falls, LDL clearance declines, and cholesterol synthesis rises44 When ADIPOR2 expression is reduced — as occurs in obesity — PPARα activity in the liver falls, LDL clearance declines, and cholesterol synthesis rises
Demonstrated in a glucocorticoid stress model showing that decreased hepatic AdipoR2 impairs AMPK–PPARα signaling with measurable effects on LDL and cholesterol. The C allele at rs11061937 may tag a haplotype with altered ADIPOR2 expression or receptor function, making the liver less responsive to adiponectin's protective metabolic signals.

The Evidence

The most direct evidence for rs11061937 comes from the Finnish Diabetes Prevention Study (DPS)55 Finnish Diabetes Prevention Study (DPS)
A landmark randomized lifestyle intervention trial in Finland enrolling people with impaired glucose tolerance (IGT); the DPS genotyping sub-study examined 484 participants for ADIPOR2 variants and cardiovascular outcomes. Eight ADIPOR2 SNPs were analyzed; four showed nominal association with CVD outcomes, and when these were entered into a joint multi-SNP model, rs11061937 remained independently significant (p = 0.014). This indicates the variant contributes unique CVD risk information above and beyond what other ADIPOR2 variants capture.

In contrast, a smaller study of 200 admixed Latin Americans found no association between rs11061937 and diabetes or hypertriglyceridemia66 no association between rs11061937 and diabetes or hypertriglyceridemia
Mora-García et al. Variations in ADIPOR1 But Not ADIPOR2 are Associated With Hypertriglyceridemia and Diabetes in an Admixed Latin American Population. Review of Diabetic Studies, 2017, while ADIPOR1 variants in the same cohort showed significant associations (OR 3.88–4.72). This population and sample size difference may reflect genuine ancestry-specific effects or limited statistical power — the C allele frequency is notably higher in East Asian and Latino populations (~50% and ~48% respectively) than in Europeans (~32%), which changes the statistical architecture of association studies considerably.

More broadly, the gene's biology is well-established: synthetic ADIPOR agonists that activate both ADIPOR1 and ADIPOR2 reduce insulin resistance and extend lifespan in obese diabetic mice77 reduce insulin resistance and extend lifespan in obese diabetic mice
Okada-Iwabu et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature, 2013, confirming the receptor system as a tractable target for metabolic disease. ADIPOR2 in particular is selectively downregulated in visceral obesity while ADIPOR1 expression is maintained88 while ADIPOR1 expression is maintained
Demonstrated in adipose tissue and liver from obese subjects; ADIPOR2 uniquely responds to the obese microenvironment with progressive downregulation, suggesting it is a key point of metabolic vulnerability.

Practical Actions

The actionable levers for ADIPOR2-related signaling are strategies that raise circulating adiponectin and maintain hepatic receptor responsiveness. Adiponectin levels respond measurably to dietary composition: reducing saturated fat intake and increasing omega-3 fatty acid consumption raise adiponectin. Regular fasting glucose and lipid panel monitoring catches early metabolic drift, since ADIPOR2 signaling deficits manifest first as rising fasting glucose and triglycerides rather than overt diabetes. Given the Finnish DPS finding linking this variant to CVD outcomes — independent of T2D progression — cardiovascular risk markers (fasting lipids, hsCRP, blood pressure) are relevant monitoring targets.

Interactions

rs11061937 was analyzed alongside rs1058322, rs10848554, and rs16928751 in the Finnish DPS; these four SNPs were co-associated with CVD risk, suggesting they tag an extended ADIPOR2 haplotype with compounded effects on receptor function. Carrying C alleles at multiple ADIPOR2 loci likely amplifies the reduction in hepatic adiponectin responsiveness. For individuals who also carry lipid metabolism risk variants (e.g., in APOE, LDLR, or the triglyceride-fatty acid pathway), the combination of impaired ADIPOR2 signaling with intrinsically dysregulated lipid handling may represent a more significant cardiometabolic risk profile than either pathway alone.

Nutrient Interactions

dietary fat altered_metabolism
glucose altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

TT Standard Receptor Function Normal

Standard ADIPOR2 function — normal hepatic adiponectin signaling

You carry two copies of the T reference allele at rs11061937. Your ADIPOR2 gene does not carry the variant associated with elevated cardiovascular disease risk in the Finnish Diabetes Prevention Study. About 47% of people globally share this genotype, and it is most common in people of European and African ancestry. Your liver's adiponectin receptor 2 is expected to function with normal efficiency in mediating fatty acid oxidation and insulin-sensitizing signals.

CT Intermediate Receptor Activity Intermediate

One copy of the ADIPOR2 risk allele — mildly reduced hepatic adiponectin signaling

ADIPOR2 is the primary liver receptor for adiponectin, mediating activation of PPARα (which drives hepatic fatty acid oxidation) and AMPK (which improves glucose uptake and suppresses fat synthesis). The rs11061937 C allele is intronic — it does not change ADIPOR2's amino acid sequence, but may tag a haplotype with altered receptor expression levels or mRNA splicing efficiency. Reduced ADIPOR2 expression has been directly linked to impaired hepatic PPARα and AMPK signaling, rising LDL, and increased cholesterol synthesis in liver tissue. As a CT heterozygote, you have one copy of the potentially lower-function allele alongside a normal reference copy, resulting in partial rather than complete impairment of adiponectin signaling.

CC Reduced Receptor Activity Reduced

Two copies of the ADIPOR2 risk allele — reduced hepatic adiponectin signaling and elevated cardiovascular risk

ADIPOR2 sits at the interface of adipose-tissue signaling and liver metabolism. When adiponectin binds ADIPOR2, the receptor activates AMPK — which suppresses hepatic fat synthesis and improves glucose uptake — and PPARα, which drives transcription of fatty acid oxidation enzymes in liver. Reduced ADIPOR2 expression or function disrupts both arms: hepatic fat accumulates, LDL clearance falls, cholesterol synthesis rises, and fasting glucose climbs. The C allele at rs11061937 is intronic and likely acts through altered gene expression rather than a structural receptor change, but the downstream consequence of reduced receptor activity is a liver that is less responsive to adiponectin's protective metabolic signals. Strategies that raise circulating adiponectin (increasing its concentration to saturate even reduced receptor density) and that independently support AMPK and PPARα pathways are the most impactful interventions for this genotype.